Innate Pharma Partners with Sobi to Advance Lacutamab into Phase 3 for Rare T-Cell Lymphoma
Innate Pharma teams up with Sobi to launch TELLOMAK-3 Phase 3 trial of lacutamab for rare T-cell lymphoma, with $75M upfront and new CMO.
/ 492 items
#XY Event-Driven Stocks↓
Why Replimune Shares Dropped Despite FDA Nod for Melanoma Drug TUDRIQEV
Investors reacted to the 24.2% ORR on the official label.
FDA to Review GRAIL’s Galleri Multi-Cancer Blood Test at September Advisory Meeting
GRAIL’s Galleri cancer blood test will be reviewed by FDA experts as the company seeks full approval for early cancer detection.
FDA Completes First-Cycle Review of NRx’s Ketamine ANDA with No Drug-Related Issues
FDA clears path for NRx’s preservative-free ketamine: no major drug issues found, only packaging certification remains.
Tarsus to Acquire Alkeus in Up to $800 Million Deal for Rare Eye Disease Drug
Tarsus to acquire Alkeus for up to $800M, adding late-stage oral therapy for Stargardt disease – a rare eye disorder with no approved treatments.
FDA Approves ORZEYFUL: First Medicine to Treat the Root Cause of Narcolepsy Type 1
Twice-daily pill improves wakefulness and reduces symptoms.